FDA opens path for TRT for low libido in idiopathic hypogonadism

Estimated reading time: 9 minutes

Key takeaways

The FDA is encouraging sNDAs to add a new TRT indication: treatment of low libido in men with idiopathic hypogonadism; this is not a blanket approval.
Signal follows a Dec 2025 expert panel review of RCTs suggesting benefit for libido in appropriately selected men with low testosterone.
The move does not apply to age-related testosterone decline; the focus is idiopathic hypogonadism only.
Safety emphasis: class warning for blood pressure increases and elevated risks of AF, AKI, and PE despite non-inferiority for MACE.
Practical impact awaits product-specific sNDA approvals, potentially extending into 2027.

Introduction
What changed in 2026—and why it matters
Idiopathic hypogonadism vs. age-related low T
What evidence the FDA considered
Safety picture in 2026
What this means for men considering TRT
Considerations for clinicians
Open questions the field is watching
Where Taurus Meds fits
Conclusion
Disclaimer
Sources

Introduction

A quiet but important regulatory shift arrived this spring: the FDA signaled openness to a new indication for testosterone replacement therapy (TRT)—treating low libido in men with idiopathic hypogonadism (unexplained low testosterone). The agency has invited manufacturers to submit supplemental applications (sNDAs) to support this specific use. While not an approval, it marks a meaningful departure from the prior, narrower framework that largely limited TRT labeling to men with known genetic or structural causes of hypogonadism.

This article unpacks what changed, why it matters, what the evidence says, and how to think about the benefits and risks if you’re exploring TRT for idiopathic hypogonadism in 2026.

What changed in 2026—and why it matters

For years, FDA-approved TRT labeling focused on men with clearly defined hypogonadism due to identifiable structural or genetic causes (e.g., pituitary or testicular disease, congenital syndromes). Men with low T of unclear etiology—commonly termed idiopathic hypogonadism—were generally outside labeled indications, especially if low T appeared age-related.

In April 2026, the FDA announced it is open to a new TRT indication focused narrowly on a symptom—low libido—in men with idiopathic hypogonadism. The agency invited manufacturers to contact FDA and submit sNDAs by April 30, 2026. The shift follows a December 2025 expert panel discussion of RCT evidence and reflects the agency’s view that carefully selected men with unexplained low testosterone may experience clinically meaningful improvements in libido with TRT.

Important caveats:

No approvals have been granted yet. Each product will need to demonstrate substantial evidence of effectiveness and a favorable risk-benefit profile for the proposed population.
The pathway is symptom-specific (low libido) and population-specific (idiopathic hypogonadism). It does not extend TRT to age-related low T or other conditions.

For men and clinicians, this could eventually mean clearer on-label access to TRT for low libido when low testosterone is present but no structural or genetic cause is found—provided safety and efficacy standards are met in sNDAs.

Idiopathic hypogonadism vs. age-related low T: the crucial distinction

Understanding the boundary between idiopathic hypogonadism and age-related decline is central to the FDA’s 2026 posture.

Idiopathic hypogonadism: Persistently low testosterone without an identifiable genetic or structural cause after appropriate evaluation. Symptoms can include low libido, fatigue, depressed mood, and reduced muscle mass. Biochemical thresholds vary by guideline (often total testosterone below ~280–350 ng/dL on morning testing), and confirmation typically requires repeat measures and clinical correlation.
Age-related hypogonadism: Lower testosterone levels commonly observed with aging, often multifactorial (health status, medications, adiposity, sleep). The current FDA signaling does not extend to late-onset, age-associated low T.

In practice, distinguishing these categories can be clinically challenging. Symptoms overlap, thresholds vary, and comorbidities complicate interpretation. The FDA’s sNDA pathway underscores the need for rigorous diagnostic criteria in submissions to ensure the right patients are targeted.

What evidence the FDA considered

The agency’s update references “rigorous, well-controlled RCT literature,” with a December 2025 expert panel review central to its shift. While specific trials cited by the panel were not fully detailed publicly, several lines of evidence inform the conversation:

Libido and sexual function: Multiple RCTs and systematic reviews report improvements in libido and erectile function among hypogonadal men treated with TRT, forming one of the most consistent benefit signals in the literature (Corona et al., 2020). This aligns with the agency’s symptom-focused lens on low libido.
Oral testosterone undecanoate (oTU): A recent meta-analysis showed oTU significantly increases testosterone in hypogonadal men versus placebo and is generally well tolerated without significant increases in adverse events compared with placebo. Notably, in eugonadal participants, oTU paradoxically decreased testosterone, reinforcing the importance of correct patient selection and avoiding therapy in men with normal baseline T (Sex Med Rev, 2023).
Body composition and metabolic markers: In men in their 40s with biochemically confirmed hypogonadism, studies report gains in lean mass, reductions in fat mass, improved insulin sensitivity, and smaller waist circumference—especially when paired with lifestyle interventions (Cureus, 2025). While encouraging, these are supportive outcomes; the FDA’s near-term pathway is explicitly tied to low libido improvement.
Limited age-related data: RCT evidence in age-related hypogonadism remains limited, with more heterogeneity and fewer trials (PubMed review, 2020). This evidence gap supports the FDA’s decision to focus on idiopathic cases rather than expand broadly to late-onset low T.

Bottom line: The clearest efficacy signal for TRT across hypogonadal populations has been sexual desire/libido and erectile function. The 2026 FDA update narrows in on that signal for a carefully defined group—men with idiopathic hypogonadism.

Safety picture in 2026: what stays the same—and what’s evolving

TRT’s safety profile remains a key part of any potential label expansion.

Blood pressure increases: In February 2025, the FDA updated TRT labeling with a class-wide warning about clinically meaningful increases in blood pressure observed across formulations, based on ambulatory BP monitoring data. A prior boxed warning for major cardiovascular events (MACE) was removed but replaced with this BP-specific warning.
Atrial fibrillation (AF), acute kidney injury (AKI), pulmonary embolism (PE): A large, contemporary randomized safety trial (TRAVERSE; 2026, in press) found non-inferiority for MACE but higher rates of AF, AKI, and PE in the testosterone group relative to placebo. Some data suggest an early risk window for venous thromboembolism in the first 3–6 months after starting therapy.
Erythrocytosis: Elevations in hematocrit are well-documented, especially with long-acting injectable formulations, and often necessitate dose adjustments or other management.
Prostate and fertility: Ongoing attention to prostate health is standard in men on TRT. Additionally, exogenous testosterone can suppress spermatogenesis, which is consequential for men considering future fertility.

The FDA’s eventual labeling for any new indication will likely continue to emphasize blood pressure monitoring, cardiovascular risk assessment, and careful surveillance for hematologic and thromboembolic events. These considerations apply across formulations (gels, injections, oral TU), with nuances that may be addressed on a product-specific basis in sNDAs.

What this means for men considering TRT for low libido

Potential benefits: Men who meet biochemical and clinical criteria may experience meaningful improvements in libido. Secondary gains in energy, mood, or body composition are reported in some studies but are not the focus of the FDA’s current pathway.
Patient selection remains crucial: The paradoxical decrease in testosterone observed with oral TU in eugonadal men underscores that TRT is not benign or universally appropriate. Precise diagnosis and ongoing monitoring matter.
Monitoring likely unchanged: Blood pressure checks, hematocrit surveillance, prostate health assessment, and cardiovascular risk review will remain part of responsible care. Early vigilance for AF, AKI, and thromboembolic events is warranted given emerging safety signals.
Timelines: Even if manufacturers meet the April 30, 2026 engagement window, FDA review of supplemental applications typically spans 6–12 months. Approvals, if granted, could extend into 2027.
Insurance and access: On-label indications often facilitate coverage, but payer policies vary. Final labeling, required monitoring, and product choice (gel, injection, oral) could influence access and out-of-pocket costs.

Considerations for clinicians

Current practice is unchanged until sNDAs are approved. Off-label prescribing remains subject to clinical judgment, but promotion beyond existing labels is restricted.
The FDA’s narrow focus on low libido in idiopathic hypogonadism is deliberate. Broader claims around depression, cardiovascular disease, or diabetes—raised by some experts—are not part of this pathway.
Documentation may matter more: Clear diagnostic workups distinguishing idiopathic hypogonadism from age-related decline will likely align with future labeling and payer expectations.
Shared decision-making: Communicate evolving evidence, the specific symptom target (libido), and safety trade-offs, particularly related to blood pressure and thromboembolic risk.

Open questions the field is watching

Which specific RCTs underpinned the December 2025 expert panel’s conclusions, and how strong are the data on libido endpoints?
What primary efficacy endpoints will FDA require for sNDA approval—validated sexual function scales, patient-reported outcomes, or biochemical targets?
How will regulatory submissions define idiopathic hypogonadism versus age-related decline in a way that is both clinically practical and scientifically rigorous?
Will approvals, if granted, include enhanced monitoring programs or restricted distribution pathways in light of AF, AKI, and PE signals?
What will the total review time be for sNDAs initiated after April 30, 2026, and when might first approvals realistically land?
How will labels incorporate the TRAVERSE trial’s non-MACE safety signals and the 2025 BP warning across formulations?

Where Taurus Meds fits

Taurus Meds follows these regulatory updates closely so patients and clinicians can make informed choices as the landscape evolves. If sNDAs are approved, we’ll help:

Track which products receive the new indication and how labeling differs by formulation.
Clarify monitoring expectations such as blood pressure and hematologic checks, and coordinate logistics where appropriate.
Share practical updates on coverage and access as payers react to any label changes.

Our goal is to keep you current on evidence and policy—so decisions about TRT for idiopathic hypogonadism remain grounded, cautious, and patient-centered.

Conclusion

The FDA’s 2026 signal is a measured step: a focused path to on-label TRT use for low libido in men with idiopathic hypogonadism, pending product-specific evidence. It does not expand TRT to age-related low T, nor does it endorse broader disease-modifying claims. The evidence for libido improvement is among the most consistent findings in hypogonadal men, but safety considerations—especially blood pressure, thromboembolic risk, AF, and AKI—remain paramount.

If you’re exploring TRT for low libido with documented low testosterone and no clear structural cause, this development may eventually widen on-label options. For now, the prudent approach is to stay informed, weigh potential benefits against known risks, and continue shared decision-making with a qualified clinician as the regulatory story unfolds.

Disclaimer

This article is for informational purposes only and is not medical advice. Decisions about testing or treatment should be made with a qualified healthcare professional who can consider your individual circumstances.